1230487-01-0

Basic information

• Product Name: 4-[(1E)-1-([[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino)ethyl]-2-ethylbenzaldehyde
• Synonyms: 4-[(1E)-1-([[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino)ethyl]-2-ethylbenzaldehyde
• CAS NO: 1230487-01-0
• Molecular Weight: 431.498
• Mol File: 1230487-01-0.mol

Chemical Properties

• CAS DataBase Reference: 4-[(1E)-1-([[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino)ethyl]-2-ethylbenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(1E)-1-([[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino)ethyl]-2-ethylbenzaldehyde(1230487-01-0)
• EPA Substance Registry System: 4-[(1E)-1-([[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino)ethyl]-2-ethylbenzaldehyde(1230487-01-0)

Safety Data

• Hazardous Substances Data: 1230487-01-0(Hazardous Substances Data)

Upstream product

• 65735-71-9 (4-chloro-3-(trifluoromethyl)phenyl)methanol 
• 1418144-62-3 1-[3-bromo-4-(hydroxymethyl)phenyl]ethan-1-one 
• 1378888-43-7 1-[3-ethyl-4-(hydroxymethyl)phenyl]ethan-1-one 
• 1418144-63-4 1-[3-ethenyl-4-(hydroxymethyl)phenyl]ethan-1-one 
• 108-94-1 cyclohexanone 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 13376-26-6 1-cyclohex-1-enyl-2-trifluoromethylbenzene 
• 1449293-48-4 1-cyclohexyl-4-methyl-2-trifluoromethylbenzene 
• 1449293-47-3 1-cyclohex-1-enyl-4-methyl-2-trifluoromethylbenzene 
• 261952-20-9 1-bromo-4-methyl-2-(trifluoromethyl)benzene 
• 1034188-31-2 2-(trifluoromethyl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-carboxylic acid 
• 89490-05-1 cyclohex-1-enylboronic acid 
• 161622-14-6 4-bromo-3-(trifluoromethyl)benzoic acid 
• 1418144-66-7 (E)-1-(3-ethyl-4-(hydroxymethyl)phenyl)ethan-1-one-O-(4-cyclohexyl-3-(trifluoromethyl)benzyl)-oxime 

Downstream Products

• 1230487-00-9 Siponimod 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF SIPONIMOD

The present invention relates to a process for the preparation of a key intermediate and other intermediates useful for the synthesis of Siponimod, a drug used for the treatment of multiple sclerosis. Object of the invention are also said novel intermediates.

PROCESS FOR MAKING SIPONIMOD AND INTERMEDIATE THEREOF

The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.

PROCESS FOR PREPARATION OF SIPONIMOD, ITS SALTS AND SOLID STATE FORMS THEREOF

The present application provides process for preparation of siponimod, intermediates of siponimod, salts of siponimod, polymorphic forms and solid dispersions of siponimod and its salts thereof. The present application specifically provides crystalline polymorphic forms of siponimod base, siponimod hemifumarate and other salts and pharmaceutical compositions thereof. Also provided are solid dispersions of siponimod hemifumarate and pharmaceutical compositions containing them.

AZETIDINE MODULATORS OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR

Described are deuterium-substituted azetidine compounds of Formula (I), which are modulators of sphingosine 1 -phosphate receptor. Also described are pharmaceutical compositions comprising the deuterium-substituted azetidine compounds, and methods of use thereof.

PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER

This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to the compound of formula I and other intermediates that are used in such processes.